anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The trial will include patients with acute spontaneous ICH, who are ≥18 years of age and are eligible for treatment within 2 hours of stroke onset. A sample size of 326 patients is calculated to give 80% power to detect a large effect size assuming mean relative ICH haematoma growth of 38% in the placebo arm compared to 19% in the active treatment arm and standard deviation of 19%, inflated for nonparametric analysis. Adaptive increase in sample size will be performed if the result of interim analysis of the first 144 patients is promising, using the methodology of Mehta and Pocock. The maximum sample size is capped at 326. Standard CT for initial diagnosis of suspected stroke patients will be performed. Neurological impairment and functional scores will be measured by a neurologist or health care professional trained in their administration. The assessors will be blinded to the treatment group. Patients eligible for the RCT will be randomised in a 1:1 ratio to receive either tranexamic acid or placebo stratified by treating centre and utilising randomly permuted blocks of random size.
specialised software for assessing the sagittal plane has arisen. Digital measuring software of many types has been proved to be faster, more accurate, more precise, and less variable than manual procedures. Angle measurement software is available in different formats and applications. Surgimap is another programme used for measuring angles. The current software has proven to be a godsend and is currently being used in the medical industry to measure joint angles especially the spine alignment. The programme is also used for scientific reasons, such as digital photo analysis. A recent study discovered that Surgimap software is a viable approach for evaluating spinal postural angles in teenagers from varied standing position perspectives using digital pictures.

As there a lack of knowledge about the reliability and validity of the surgimap software to measure the Q- angle. Therefore, The study will investigate the inter-rater, intra-rater reliability and concurrent validity of the surgimap software for measuring the Q-angle.
PURPOSE: A process of preparing egg white protein hydrolysate improved in flavoring by hydrolyzing egg white protein with protease is provided. Whereby, the product is not decomposed in the body by angiotensin converting enzyme while having excellent inhibitory activity on angiotensin converting enzyme, has excellent antihypertensive properties, is convenient to eat and can be used as a protein supply source. CONSTITUTION: A protease is added to an aqueous egg white protein solution in the amount of 0.1 to 5% and reacts at 30 to 50deg.C and a pH of 6 to 9 for 4 to 48hr. The protease is one or more selected from the group consisting of Protamex(derived from Bacillus), MP(Aspergillus melleus), LP(Aspergillus oryzae), Flavourzyme(Aspergillus oryzae), neutrase, alcalase, Bacillus licheniformis, Promod 192(derived from Aspergillus). For example, egg white is dissolved in water at 55 to 60deg.C, cooled and added with 1% Protamex at a pH of 7. Then the solution reacts at 47deg.C for 28hr and is maintained at 90deg.C for 15min to inactivate enzyme.
A long established risk factor for late renal allograft loss is the development of DSA. Recent studies from our group and others have shown that these antibodies are probably responsible for chronic rejection by attacking the vascular endothelium and fixing complement (detected as C4d in renal biopsies). Studies in humans and monkeys have shown that circulating antibody and complement deposition precede the development of chronic graft injury. Interruption of antibody production is a potential beneficial strategy to prevent late graft loss from this mechanism.

Therapeutic regimens that have been used in an attempt to deplete HLA or ABO antibodies include plasmapheresis, IVIg, tacrolimus and mycophenolate mofetil (MMF), and anti-CD20 (rituximab). Of these regimens, the most specific is anti-CD20, rituximab (rituxan), a therapy now FDA approved for B cell proliferative diseases. Although initially introduced for the treatment of neoplasm, the humoral immunosuppressant effects of rituximab have been shown to have clinical significance. Rituximab interferes with both primary and secondary humoral responses by eliminating B-cells prior to antigen exposure, thus interfering with differentiation into antibody secreting cells and specific antibody production.
The application provides an antibacterial polypeptide silver nanoparticle, a preparation method and application thereof, an antibacterial composition and a use method thereof, and belongs to the technical field of antibiosis. The antibacterial polypeptide silver nanoparticle comprises: silver nanoparticles and connectionsAt least two polypeptide ligands on the silver nanoparticles. The structure of the polypeptide ligand is PEG-Lys-Arg n ‑Gly‑His n Cys, polypeptide ligand linked to silver nanoparticle via PEG-terminated thiol group. Arg n 4 to 6 Arg are connected end to end in sequence and His n 4-6 His are connected end to end in sequence, and the quantity of Arg and His is equal. The weight average molecular weight of PEG is 3400-5000. The antibacterial polypeptide silver nanoparticles have the capability of pH response targeted aggregation, can be accumulated and retained in bacterial plaque organisms, and are beneficial to the slow release of silver ions in an infected area, so that the aim of removing bacterial plaque biomembranes is fulfilled, and better antibacterial property is realized.
The nuclear factor erythroid 2-related factor 2 (Nrf2) is overexpressed in multiple tumor cells. Nevertheless, the role of Nrf2 in malignant transformation induced by hydroquinone (HQ) is unknown. Here, we hypothesized that Nrf2 might participate in HQ-induced malignant transformation of TK6 cells, a line of normal human lymphoblastoid cells, by accelerating cell proliferation and regulating cell cycle progression. The data indicated that TK6 cells chronically exposed to HQ continuously activated Nrf2-Keap1 signaling pathway. Furthermore, we found that defects in Nrf2 inhibited cell proliferation and prevented cells from entering S phase from G1 phase. Mechanistically, Nrf2 is involved in cell cycle abnormalities induced by prolonged exposure to HQ by binding to p16, thereby activating the p16/Rb signaling pathway. Taken together, Nrf2 might be a potential driver of carcinogenesis that promotes malignant cell proliferation and affects cell cycle distribution.
The invention relates to a DNA nano drug-loading system for loading chemotherapy-phototherapy combined drugs based on thermodynamic guidance, wherein the molar ratio is AS1411NTrs: TBO: DOX =1:2: 3. The application of a DNA nano-drug-loaded system loaded with chemotherapy-phototherapy combined drugs based on thermodynamic guidance in cancer treatment. The invention studies AS1411NTrs loaded with DOX and TBO combination drugs simultaneously. The interaction of free TBO with AS1411NTrs, and the interaction of DOX + TBO combination drug with AS1411NTrs were studied using Isothermal Titration Calorimetry (ITC), Differential Scanning Calorimetry (DSC), and fluorescence spectroscopy to obtain binding patterns and corresponding thermodynamic parameters. In addition, the in-vitro drug release behavior and the anti-tumor effect of AS1411NTrs which are cooperatively loaded with the DOX and TBO combined drug are researched. The invention provides theoretical guidance for the combined treatment of DOX and TBO to effectively overcome multi-drug resistance.
Bevacizumab 5 mg/kg IV over 90 minutes on Day 1 and 22 (every 3 weeks) of 6 week cycle. Lomustine starting dose of 75 mg/m2 administered orally at sleep time on Day 3 of every 6 week cycle.
In the U.S., screening by prostate-specific antigen (PSA) is widespread and considered to be an effective early detection screen for prostate cancer although there are some problems associated with its use. Only about 30-40% of men with elevated PSA are diagnosed with cancer on initial biopsy. The other 60-70% are diagnosed with either benign prostatic hyperplasia or low-or high-grade prostatic intraepithelial neoplasia (LGPIN or HGPIN). Due to their persistent elevated PSA levels, men undergo repeat biopsies where many are subsequently diagnosed with cancer (the false negative rate for biopsies with pathological diagnoses of benign or LGPIN has been reported to be 13-19% and for HGPIN from 50-70%). We propose to conduct a pilot study to evaluate whether (i) the addition of molecular markers (e.g., tumor-specific gene methylation of GSTPI, CD44, Annexin II, and Caveolin 1) detectable in serum and/or urine sediments after prostatic massage can improve the prediction of prostate cancer and (ii) addition of tumor-specific gene methylation detectable in core-needle biopsy specimens can improve the sensitivity of core-needle biopsy in the diagnosis of prostate cancer among patients screened at two Urology clinics located at Howard University, Washington, DC and Madigan Army Medical Center, Tacoma, WA. Preliminary studies have shown detection of hypermethylated genes in urine sediments after prostatic massage in men with elevated PSA (greater than 4ng/ml) improved the specificity of PSA from 73% to 98%. Further, DNA hypermethylation of tumor-specific genes was also identified in serum. In our laboratory, we have developed assays for evaluating DNA hypermethylation of several genes shown to be important in prostate carcinogenesis. These assays are highly sensitive (able to detect down to about 20 tumor cells with methylated DNA) and specific (can distinguish methylated from normal DNA from in a ratio of 1 tumor cell in 10,000 normal cells), and could serve to add value to current prostate cancer screening modalities.
The diagnosis of acute lymphoblastic leukemia (ALL), which is the most common type of cancer in children, has become more accurate with the use of flow cytometry. Here, this technology was used to immunophenotype leukemic cells in peripheral blood samples from Libyan pediatric ALL patients. We recruited 152 newly diagnosed patients at Tripoli Medical Center (Tripoli, Libya) by morphological examination of blood and bone marrow. Twenty-three surface and cytoplasmic antigen markers were used to characterize B and T cells in circulating blood cells by four-color flow cytometry. Six children (3.9%) turned out to have biphenotypic acute leukemia, 88 (57.9%) had B ALL, and 58 (38.1%) had T ALL. There were 68 cases of pro-B ALL CD10-positive (44.7%), 8 cases of pro-B ALL CD10-negative (5.2%), 6 cases of pre-B ALL (3.9%), and 6 of mature-B ALL (3.9%). CD13 was the most commonly expressed myeloid antigen in ALL. We present immunophenotypic data for the first time describing ALL cases in Libya. The reported results indicate that the most common subtype was pro-B ALL, and the frequency of T-ALL subtype was higher compared to previous studies. Six cases were positive for both myeloid and B lymphoid markers. Our findings may provide the basis for future studies to correlate immunophenotypic profile and genetic characteristics with treatment response among ALL patients.
Diabetes mellitus (DM) is a major risk factor for tuberculosis (TB), though the underlying mechanisms linking DM and TB remain ambiguous. Macrophages are a key player in the innate immune response and their phagocytic ability is enhanced in response to microbial infections. Upon infection or inflammation, they also repel invading pathogens by generating; reactive oxygen species (ROS), reactive nitrogen species (RNS), pro-inflammatory cytokines (IL-1β and IL-6), and anti-inflammatory cytokines (IL-10). However, the robustness of these innate defensive capabilities of macrophages when exposed to hyperglycemia remains unclear. In our current work, we explored the production of these host defense molecules in response to challenge with Mycobacterium tuberculosis (Mtb) infection and lipopolysaccharide (LPS) stimulation. Utilizing peritoneal macrophages from high-fat diet + streptozotocin induced diabetic mice and hyperglycemic THP-1-derived macrophages as model systems; we found that LPS stimulation and Mtb infection were ineffective in stimulating the production of ROS, RNS, and pro-inflammatory cytokines in cells exposed to hyperglycemia. On the contrary, an increase in production of anti-inflammatory cytokines was observed. To confirm the mechanism of decreased anti-bacterial activity of the diabetic macrophage, we explored activation status of these compromised macrophages and found decreased surface expression of activation (TLR-4) and differentiation markers (CD11b and CD11c). We postulate that this could be the cause for higher susceptibility for Mtb infection among diabetic individuals.
The purpose of this study is to discover more about how the human body and the bacteria living in our intestines, known as "gut flora," react to different foods a person may consume. The investigators want to know if there are differences in compounds measured in a participant's blood and urine after eating different foods. Specifically, the investigators are interested in seeing if there are differences in these compounds after eating ultra-processed foods, like hamburgers and french fries, versus eating whole foods, like fresh fruits and vegetables. The investigators also want to know if the bacteria in our intestines may change the levels of these compounds. To this end, some subjects will be asked to take antibiotics to suppress the gut flora for three days before eating the challenge meal. Suppression of gut flora is a known effect of the antibiotics used in this study. Participants will have two study visits.
The present invention relates to methods of ex-vivo modification of mammalian tissue, via genetic transformation or introduction of cells, followed by implantation of the modified tissue into a patient in need thereof. Preferably, the tissue is microvascular free flap (or microvascular bed) tissue. A tissue explant is detached from the native circulation of a donor, transfected ex vivo, and then attached (anastomosed) to a recipient, either the donor or another patient. In a preferred embodiment, the mammalian tissue is human tissue and the patient is a human patient. Transfection with a nucleic acid encoding a product of interest is performed by contacting the selected tissue with a vector, preferably a viral vector, most preferably an adenoviral vector, that comprises the nucleic acid encoding the product of interest. The nucleic acid encoding the product of interest is driven by regulatory element such as an inducible, constitutive or cell-specific promoter, preferably an inducible or constitutive promoter. After genetic transformation of the selected tissue, the tissue is flushed to remove the vector not incorporated into the cells of the tissue. The tissue is then attached to the native circulation of the recipient using microvascular techniques. In one aspect, the invention provides methods of local delivery of a product (protein) of interest. In another aspect, the invention provides methods of systemic delivery of a product of interest. In yet another aspect, the invention provides methods of both local and systemic delivery of a product of interest. In yet another aspect, the invention provides methods for producing a “neo-organ,” i.e., a non-naturally occurring vascularized tissue that provides a function of a gland or organ, or that supplements the function of a gland or organ, and that delivers locally or systemically a product of interest to a patient in need thereof.
American adults have a high prevalence of overweight, obesity and prediabetes. Small weight loss delays the progression to type 2 diabetes and decrease cardiovascular risk, yet adherence to long term calorie restriction is difficult to sustain. There is an urgency to find effective, easy-to implement and sustain, and affordable life style interventions. Restricting the food intake interval, or time restricted eating (TRE) has been shown in small-scale pilot studies to result in weight loss and improve metabolism, while being less challenging than calorie count. We propose to rigorously assess the efficacy and sustainability of self-monitoring with and without TRE, administered via a smartphone application, on weight loss and decreased cardiovascular risk. To achieve this goal, metabolically unhealthy mid-life adults with overweight or obesity who habitually eat for more than 13h/day, will be randomized to a self monitoring and restricted eating window to 10h/d (TRE) or to a self-monitoring and habitual eating window (13h, HABIT), and followed up to 12 months. Ambulatory measures of food intake, sleep, physical activity and glucose, and outpatient well controlled studies will be done to determine the effect of TRE versus habitual eating duration (HABIT), as well as the mediators of these effects. Hypotheses: 1) TRE vs. HABIT will result in decreased fat mass, measured by quantitative magnetic resonance, and effect mediated via decreased daily total energy intake, measured by double labeled water; 2) TRE vs. HABIT will result in lower insulin resistance, lower glycemia and shift in fuel utilization preferentially to lipid mobilization; 3) Adherence to the TRE intervention will be associated with greater weight loss at 3 months and weight maintenance at 12 months. Results from this study will provide important insights into understanding the physiological and molecular interactions between restricting daily eating interval and metabolic function, and could provide evidence for using TRE interventions to improve metabolic health and decrease cardiovascular risk in the large number of mid-life and older Americans in great need of life style intervention.
Colorectal cancer (CRC) is a common malignancy worldwide and tumour stage is closely related to clinical outcome. A small but significant proportion of submucosal-invasive (ie, pT1) CRC are associated with regional lymph node metastases (LNM) and a worse prognosis. The likelihood of LNM in pT1 CRC needs to be balanced against the operative risk and costs of surgical resection when determining the best patient management. A wide range of histopathological and clinical factors may affect LNM risk in this setting. This script provides a comprehensive overview of the tumour and patient-associated features that have been linked to LNM risk in pT1 CRC. Some of the features are well established within the literature and are included in published guidelines, while others are novel and emerging in nature. Odds ratios for LNM that are associated with key predictive features are provided where appropriate, and published models developed as an aid to the calculation of LNM risk are discussed.
BACKGROUND/OBJECTIVES: The goal of this pilot study is to evaluate adherence to the Mediterranean Food Pattern (MFP) in a self-selected sample of university students, addressing a perspective of food sustainability. In addition, it seeks to relate adherence to MFP with sociodemographic characteristics and nutritional status.
METHODS: This is a cross-sectional pilot study whose data collection was carried out by an online questionnaire between January and April 2023.
RESULTS: Two hundred and forty-eight students participated-most of them were female (78.2%), had a median of 22 (20; 30) years, resided in the central region of Portugal (42.3%), and were pursuing a degree (73.4%) in a public higher education institution (66.5%). The prevalence of overweight (overweight and obesity) found was 33.1%. Females predominantly used olive oil as their main source of fat (95.9%, p = 0.009) and had a higher consumption of sugary drinks (81.4%, p = 0.004) compared to males, who reported usage rates of 85.2% and 63.0%, The median score of the Mediterranean Diet Adherence Screener was 7 points, presented with an interquartile range (Q1: 6, Q3: 8), indicating moderate adherence. The analysis showed no differences between the sexes (p = 0.087). There was also a negative correlation between adherence to the MFP and the body mass index (p = 0.007; r = -0.171). In addition, adherence to the MFP was associated with the area of study and the course attended, with students in health-related fields showing higher adherence.
CONCLUSIONS: These findings underscore the necessity for targeted interventions aimed at promoting adherence to the MFP among university students, which could contribute to improved health outcomes and enhanced environmental sustainability.
Lanthanide luminescent hydrogels have broad application prospects in various fields. However, most of lanthanide hydrogels possess relatively simple functions, which is not conducive to practical applications. Therefore, it is becoming increasingly urgent to develop multifunctional hydrogels. Herein, a multifunctional chitosan-based lanthanide luminescent hydrogel with ultra-stretchability, multi-adhesion, excellent self-healing, emission color tunability, and good antibacterial ability was prepared by a simple one-step free radical polymerization. In this work, our designed lanthanide complexes [Ln(4-VDPA)3] contain three reaction sites, which can be copolymerized with N-[tris(hydroxymethyl) methyl] acrylamide (THMA), acrylamide (AM), and diacryloyl poly(ethylene glycol) (DPEG) to form the first chemical crosslinking network, while hydroxypropyltrimethyl ammonium chloride chitosan (HACC) interacts with the hydroxyl and amino groups derived from the chemical crosslinking network through hydrogen bonds to form the second physical crosslinking network. The structure of the double network as well as the dynamic hydrogen bond and lanthanide coordination endow the hydrogel with excellent stretchability, adhesion and self-healing properties. Moreover, the introduction of lanthanide complexes and chitosan makes the hydrogel exhibit outstanding luminescence and antibacterial performances. This research not only realizes the simple synthesis of multifunctional luminescent hydrogels, but also provides a new idea for the fabrication of biomass-based hydrogels as intelligent and sustainable materials.
Neuropathic pain is the most excruciating symptom in peripheral neuropathy such as diabetic or chemotherapy-induced neuropathy. Management of neuropathic pain is a challenging clinical problem because only less than 50% patients are responsive to pharmacological treatment. Neuropathic pain is naturally considered as a direct consequence of peripheral nerve injury that induces hypersensitivity or ectopic activities in nociceptive nerve terminals. Nevertheless, maladaptive changes in the pain-related networks of the brain also play a crucial role in the generation, amplification, and drug-resistance of neuropathic pain. The proposed project aims to explore possible neuromodulatory effects of transcranial direct current stimulation (tDCS) on neuropathic pain caused by peripheral neuropathy. tDCS is a non-invasive stimulation technique that delivers a low-intensity current into the brain to modulate the synaptic plasticity of cortical neurons. To investigate the instantaneous effects of tDCS, tDCS will be performed through an MRI-compatible stimulation setting during functional magnetic resonance imaging (fMRI) scanning. The stimulation target of tDCS will be the primary motor cortex (M1) and the dorsolateral prefrontal cortex (DLPFC). This simultaneous tDCS-fMRI approach will enable us to (1) identify the neural substrates of neuropathic pain that could be modulated by neurostimulation, (2) to characterize the spatial patterns of functional hemodynamic brain responses following tDCS, and (3) to assess changes in cortical excitability and neuroplasticity associated with pain perception after non-invasive brain stimulation. We expect that results from the current project will advance the understanding of neuromodulatory mechanisms of tDCS and facilitate the development of treatment strategies for patients with neuropathic pain.